Geron Corporation (NASDAQ:GERN) will be discussing 3Q20 financial results with the investment community.on 5th November 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.geron.com
Earnings Expectation
Geron Corporation is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, GERN is expected to report 3Q20 loss of $ 0.06 per share from revenue of $ 0.04 million.
For the full year, analysts anticipate top line of $ 0.20 million, while looking forward to loss of $ 0.25 per share bottom line.
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.
